TY - JOUR T1 - Circulating CD8+ MAIT cells correlate with improved outcomes in anti-PD1 treated melanoma patients JF - medRxiv DO - 10.1101/2020.08.20.20178988 SP - 2020.08.20.20178988 AU - Victoria M. Vorwald AU - Dana M. Davis AU - Robert J. Van Gulick AU - Robert J. Torphy AU - Jessica S.W. Borgers AU - Jared Klarquist AU - Kasey L. Couts AU - Carol M. Amato AU - Dasha T. Cogswell AU - Mayumi Fujita AU - Timothy Davis AU - Catherine Lozupone AU - Theresa M. Medina AU - William A. Robinson AU - Laurent Gapin AU - Martin D. McCarter AU - Richard P. Tobin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/23/2020.08.20.20178988.abstract N2 - While much of the research concerning factors associated with responses to immunotherapies focuses on the contributions of conventional peptide-specific T cells, the role of unconventional T cells, such as mucosalassociated invariant T (MAIT) cells, in human melanoma remains largely unknown. MAIT cells are innate-like T cells expressing a semi-invariant T cell receptor restricted to the non-classical MHC class I molecule MR1 presenting vitamin metabolites derived from bacteria. In this prospective clinical study, we sought to characterize MAIT cells in melanoma patients and determine their association with clinical outcomes. We identified tumor-infiltrating MAIT cells in melanomas across metastatic sites and found that the number of circulating MAIT cells is reduced in melanoma patients. However, circulating MAIT cell frequency is restored by anti-PD1 treatment in responding patients, correlating with treatment responses in which patients with high frequencies of MAIT cells exhibited improved overall survival. These data provide evidence for leveraging MAIT cells and their functions as novel targets for future therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The National Institutes of Health R21CA245432 to MDM, CL, LG, and TMM. Further support was provided by the University of Colorado Anschutz Medical Campus Academic Enrichment Fund, University of Colorado GI and Liver Innate Immunity Program, the Colorado Clinical and Translation Sciences Institute, The Moore Family Foundation, the Patten-Davis Foundation, and University of Colorado Cancer Center Support Grant (P30CA046934).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All melanoma patients provided provided written informed consent according to the Colorado Multiple Institutional Review Board (COMIRB) Protocol 05-0309. Peripheral blood was obtained from healthy adult donors from the Childrens Hospital Colorado Blood Bank COMIRB 16-2367 and 17-0110.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the figures and supplementary information. ER -